Burlington Stores Inc vs CVS Health Corp — how do they compare? Burlington Stores Inc trades at $359.42 (market cap $23.38B), while CVS Health Corp trades at $93.7 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 5.2× Burlington Stores Inc's market cap, and CVS Health Corp pays a 2.78% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BURL | CVS | |
|---|---|---|
Market Cap | $23.38B | $122.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $110.60 |
52-Week Low | $242.43 | $65.51 |
Enterprise Value | $28.51B | $184.71B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $368.96, showing slight weakness with a 0.59% decline but remains near recent highs. The stock maintains strong technical momentum with bullish moving averages and trades above key support levels. Fundamentally, the company demonstrates robust earnings performance with three consecutive quarterly beats and improving profitability margins. Recent news highlights Burlington's successful smaller-store strategy driving sales productivity and upgraded analyst ratings.
The outlook remains positive with 94% analyst buy ratings and a $367 consensus target. Growth catalysts include continued store expansion and operational efficiency gains, though risks include competitive retail pressures and potential consumer spending volatility. The stock's premium valuation requires sustained execution to justify current levels.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →